再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09688 再鼎医药

未开盘 08-20 16:09:09

20.700

+0.380

+1.87%

最高21.420	最低20.480	成交量1,791万
今开20.900	昨收20.320	日振幅4.63%
总市值235.57亿	流通市值235.57亿	总股本11.38亿
成交额3.73亿	换手率1.57%	流通股本11.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":20.7,"timestamp":1787213349011,"preClose":20.32,"halted":0,"volume":17909900,"delay":0,"changeRate":0.018700787401574753,"floatShares":1138000000,"shares":1138000000,"eps":-1.2570160164399893,"marketStatus":"未开盘","change":0.38,"latestTime":"08-20 16:09:09","open":20.9,"high":21.42,"low":20.48,"amount":372713028,"amplitude":0.04626,"askPrice":20.7,"askSize":110300,"bidPrice":20.66,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-1.3357099157607417,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":0,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":20.32,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":1.3773704689809465,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688","defaultTab":"news","newsList":[{"id":"2660020034","title":"mRNA癌症疫苗实现历史性突破 易方达生物医药ETF(03186)港美股双布局捕捉创新红利","url":"https://stock-news.laohu8.com/highlight/detail?id=2660020034","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660020034?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:45","pubTimestamp":1787215545,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月19日，Moderna与默沙东公布，个人化mRNA癌症疫苗联合Keytruda，在黑色素瘤三期试验期中分析达标。截至2026年8月20日，易方达生物医药ETF  是港交所上市生物医药主题ETF中，唯一同时配置港股及美股生物医药成分的产品。这些成份股的均衡配置，让该ETF能够捕捉医药板块的整体修复行情。本次mRNA癌症疫苗达标，再次说明医疗创新本身就是科技突破，而不只是防御型板块。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK1587","02162","BK1574","LU2488822045.USD","159929","LU0196878994.USD","03186","159646","06990","09688","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126297220","title":"异动解读｜再鼎医药盘中上涨5.02%，艾加莫德自身免疫性肌炎3期临床取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1126297220","media":"行情直击","labels":["dataReport"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126297220?lang=zh_cn&edition=full","pubTime":"2026-08-20 11:34","pubTimestamp":1787196891,"startTime":"0","endTime":"0","summary":"8月20日，再鼎医药盘中上涨5.02%，报21.34港元，成交额1.68亿港元。消息面上，合作伙伴argenx于8月17日宣布，核心产品FcRn拮抗剂艾加莫德治疗成人自身免疫性肌炎的ALKIVIA 3期临床研究取得积极顶线结果。argenx此前已将艾加莫德在大中华区的开发和商业化权益独家授予再鼎医药，再鼎亦参与了该全球研究的大中华区临床开发和患者入组。若该适应症后续获批，再鼎有望进一步拓展艾加莫德在中国自身免疫疾病领域的商业化版图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药盘中上涨5.02%，艾加莫德自身免疫性肌炎3期临床取得积极结果","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660419415","title":"港股异动 | 再鼎医药(09688)早盘涨近7% argenx FcRn靶向药3期成功 再鼎拥有大中华区权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419415","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660419415?lang=zh_cn&edition=full","pubTime":"2026-08-19 11:10","pubTimestamp":1787109029,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药(09688)早盘涨近7%，截至发稿，涨4.61%，报20.18港元，成交额1.31亿港元。消息面上，据药研网报道，8月17日，免疫学公司argenx宣布，核心产品FcRn拮抗剂(艾加莫德α)旗治疗成人自身免疫性肌炎的ALKIVIA 3期临床研究取得积极顶线结果。值得注意的是，argenx此前已将艾加莫德在大中华区的开发和商业化权益独家授予再鼎医药。值得注意的是，ALKIVIA研究本身是由argenx发起的3期全球研究，再鼎医药也参与了大中华区的临床开发和患者入组，若该适应症后续在全球获批，再鼎有望进一步拓展艾加莫德在中国自身免疫疾病领域的商业化版图。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4548","BK4531","ZLAB","BK4585","BK1161","09688","KCAI","BK4526","BK4139","VXUS","BK1574","BK1588","LU2488822045.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660419413","title":"港股异动 | 再鼎医药(09688.HK)早盘涨近7% argenx FcRn靶向药3期成功 再鼎拥有大中华区权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419413","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660419413?lang=zh_cn&edition=full","pubTime":"2026-08-19 11:10","pubTimestamp":1787109029,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2488822045.USD","BK1161","BK1574","09688","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194372234","title":"异动解读｜再鼎医药盘中上涨6.27%，艾加莫德3期临床成功叠加券商首予增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1194372234","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194372234?lang=zh_cn&edition=full","pubTime":"2026-08-19 09:52","pubTimestamp":1787104357,"startTime":"0","endTime":"0","summary":"8月19日，再鼎医药盘中上涨6.27%，报20.46港元，成交额6257.6万港元。消息面上，再鼎医药合作伙伴argenx的FcRn靶向药艾加莫德三期临床试验取得成功，再鼎医药享有大中华区权益。公司披露艾加莫德正持续被评估用于多种自身免疫性风湿疾病，临床数据显示患者改善在治疗初期即已显现并贯穿整个研究周期，在免疫介导神经肌肉病及糖尿病亚组中治疗效应高度一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药盘中上涨6.27%，艾加莫德3期临床成功叠加券商首予增持评级","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170322439","title":"再鼎医药：艾加莫德持续拓展自身免疫风湿病适应症评估","url":"https://stock-news.laohu8.com/highlight/detail?id=1170322439","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170322439?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:06","pubTimestamp":1786961174,"startTime":"0","endTime":"0","summary":"再鼎医药近日披露，其核心在研药物艾加莫德正持续被评估为多种自身免疫性风湿疾病的潜在治疗选择。目前，再鼎医药正与合作伙伴协同推进多项临床研究，旨在全面评估艾加莫德在不同风湿免疫病种中的疗效与安全性。市场观察人士指出，艾加莫德适应症的持续扩展，不仅可能重塑自身免疫疾病的市场格局，亦或为再鼎医药的长期增长注入新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","LU2488822045.USD","BK1588","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136553189","title":"再鼎医药：患者改善在研究中早期显现并持续存在；免疫介导神经肌肉病与糖尿病治疗效应保持一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1136553189","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136553189?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:01","pubTimestamp":1786960870,"startTime":"0","endTime":"0","summary":"再鼎医药（ZAI LAB）披露了其临床试验的最新进展。研究结果显示，患者的改善情况在治疗初期即已清晰可见，并且这种积极态势在整个研究周期内得到了稳固的维持。值得注意的是，无论是在免疫介导神经肌肉病（IMNM）还是糖尿病（DM）亚组中，所观察到的治疗效应均展现出高度的一致性，这进一步印证了该疗法潜在的广泛适用性与可靠性。该数据无疑为再鼎医药在相关治疗领域的布局增添了有力的循证支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1161","09688","BK1574","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118648504","title":"异动解读｜再鼎医药盘中下跌5.29%，绩后累涨逾三成后回调叠加生物科技板块整体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1118648504","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118648504?lang=zh_cn&edition=full","pubTime":"2026-08-14 09:42","pubTimestamp":1786671722,"startTime":"0","endTime":"0","summary":"8月14日，再鼎医药盘中下跌5.29%，报19.51港元，成交额4631.99万港元。公司自8月6日公布Q2业绩以来股价累计涨幅超三成，短期获利回吐压力显现。板块层面，生物科技行业今日整体承压，康方生物跌2.99%、百济神州跌1.91%、三生制药跌1.29%。基本面上，虽RTW基金近日连续斥资约3.68亿美元大幅增持彰显信心，但有机构指出则乐面临竞品集采压力、艾加莫德价格承压，并下调盈利预测，短期估值快速修复后市场对中期盈利能力分歧加大。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659199950","title":"【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2659199950","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659199950?lang=zh_cn&edition=full","pubTime":"2026-08-14 08:58","pubTimestamp":1786669118,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。传统药物开发过程花费时间长成本高，且成功率较低，随着已有靶点的新药陆续获批，新药开发难度逐渐上升。近年来AI特别是深度学习的发展，促进了其在包括靶点筛选、分子生成及优化、ADMET预测、晶型预测以及合成路线筛选等的应用，AI用于大分子药物的开发投入也持续增长。AIDD有望重塑早期药物发现的流程，大大加速早期药物筛选的效率及成功率，相关干实验投入的增加以及对湿实验需求持续的增长，有望为下游产业链持续带来增量。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988188","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","LU2778985437.USD","BK1500","LU0348735423.USD","AGIX","KURE","LU0348827113.USD","01477","03933","01099","LU2328871848.SGD","AIPO","LU0417516571.SGD","LU0540923850.HKD","02268","02367","BK1191","02196","601066","LU0640798160.USD","QTOC","LU0348766576.USD","02228","KCE","LU0828237510.HKD","06160","LU1770034418.SGD","SG9999004311.SGD","VTHR","09688","LU0561508036.HKD","LU1303224171.USD","09926","LU0634319403.HKD","06821","LU2476274308.USD","CHAT","LU1719994722.HKD","LU0348825331.USD","LU0348784397.USD","LU2476274720.SGD","BK1197","LU0348783233.USD","LU0417516738.SGD","ARTY","01789","BK1515","01530","IE00B5MMRT66.SGD","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179669177","title":"再鼎医药：Roderick Wong增持美股","url":"https://stock-news.laohu8.com/highlight/detail?id=1179669177","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179669177?lang=zh_cn&edition=full","pubTime":"2026-08-13 17:12","pubTimestamp":1786612320,"startTime":"0","endTime":"0","summary":"Roderick Wong于2026年8月12日以每股均价25.41美元买入再鼎医药股份476.54万股，涉资约1.21亿美元。Roderick Wong此次增持前持有再鼎医药好仓7681.48万股，占比6.75%；增持后持股量为8158.01万股，好仓比例升至7.17%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179301927","title":"再鼎医药：RTW Fund Group GP, LLC增持美股","url":"https://stock-news.laohu8.com/highlight/detail?id=1179301927","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179301927?lang=zh_cn&edition=full","pubTime":"2026-08-13 17:11","pubTimestamp":1786612295,"startTime":"0","endTime":"0","summary":"RTW Fund Group GP, LLC于2026年8月12日以每股均价25.41美元买入再鼎医药股份476.54万股，涉资约1.21亿美元。RTW Fund Group GP, LLC此次增持前持有再鼎医药好仓7681.48万股，占比6.75%；增持后持股量为8158.01万股，好仓比例升至7.17%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132705929","title":"再鼎医药：RTW Investments, LP增持美股","url":"https://stock-news.laohu8.com/highlight/detail?id=1132705929","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132705929?lang=zh_cn&edition=full","pubTime":"2026-08-13 17:11","pubTimestamp":1786612279,"startTime":"0","endTime":"0","summary":"RTW Investments, LP于2026年8月12日以每股均价25.41美元买入再鼎医药股份476.54万股，涉资约1.21亿美元。RTW Investments, LP此次增持前持有再鼎医药好仓7681.48万股，占比6.75%；增持后持股量为8158.01万股，好仓比例升至7.17%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129891022","title":"再鼎医药（09688）审计委员会定于8月25日审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1129891022","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129891022?lang=zh_cn&edition=full","pubTime":"2026-08-13 17:05","pubTimestamp":1786611933,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司8月13日公告称，公司董事会审计委员会将于2026年8月25日／2026年8月26日召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计简明合并业绩，并按香港联合交易所有限公司证券上市规则发布中期业绩。\\n\\n公告显示，再鼎医药此前已披露截至2026年6月30日止三个月及六个月的未经审计简明合并业绩，并于2026年8月6日向美国证券交易委员会以Form 10-Q形式提交了相应季度报告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659913272","title":"港股收盘(08.13) | 恒指收跌0.17% 腾讯(00700)绩后跌超4% 联想集团(00992)飙涨20%创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2659913272","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659913272?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:33","pubTimestamp":1786610019,"startTime":"0","endTime":"0","summary":"截至收盘，恒生指数跌0.17%或43.66点，报25396.51点，全日成交额2637.1亿港元；恒生国企指数跌0.23%，报8426.49点；恒生科技指数涨0.33%，报4792.39点。蓝筹股表现联想集团创历史新高。截至收盘，联想集团涨20.18%，报34.9港元；华勤技术涨10.4%，报77.5港元。Coherent预计第一财季营收22亿至24亿美元，预计第一财季调整后每股收益为1.85至2.05美元，均高于市场预期。截至收盘，涨19.73%，报71港元。耐世特绩后大涨。调整将于8月31日收盘后生效实施。腾讯控股全天承压。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ESPO","00325","KWEB","00700","TCHmain","07300","EDZ","82800","09688","83115","ODDS","EMCS","FDNI","03419","BKF","FFEM","SOCL","09115","MHImain","07500","02833","HSI","HTCD.SI","00992","02800","CXSE","JEMA","BIDD","JADE","HHImain","07200","513600","HSImain","GAMR","LDEM","LNVGY","KCAI","XSOE","03037","IEMG","TCHI","TCEHY","03115","03330","VXUS","EEMX","EMC","AAXJ","MCHmain","80992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148734775","title":"异动解读｜再鼎医药盘中上涨5.03%，RTW基金斥资2.47亿美元大幅增持叠加绩后行情延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1148734775","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148734775?lang=zh_cn&edition=full","pubTime":"2026-08-13 10:37","pubTimestamp":1786588638,"startTime":"0","endTime":"0","summary":"8月13日，再鼎医药盘中上涨5.03%，报20.66港元，成交额1.73亿港元。消息面上，RTW Fund Group GP, LLC于8月11日以每股均价26.05美元买入再鼎医药947.45万股，涉资约2.47亿美元，增持后持股比例由5.97%升至6.75%。此外，公司此前公布的二季度业绩显示，产品收入净额1.058亿美元，环比增长11%，超出市场预期约250万美元。花旗看好其中国业务下半年企稳，核心管线Zoci获欧洲药品管理局孤儿药资格认定，后续ESMO临床数据有望带来进一步催化，绩后股价已累涨超三成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163563762","title":"再鼎医药：RTW Fund Group GP, LLC增持美股","url":"https://stock-news.laohu8.com/highlight/detail?id=1163563762","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163563762?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:14","pubTimestamp":1786526054,"startTime":"0","endTime":"0","summary":"RTW Fund Group GP, LLC于2026年8月11日以每股均价26.05美元买入再鼎医药947.45万股，涉资约2.47亿美元。RTW Fund Group GP, LLC此次增持前持有再鼎医药好仓6734.03万股，占比5.97%；增持后持股量为7681.48万股，好仓比例升至6.75%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146912959","title":"再鼎医药：RTW Investments, LP增持美股","url":"https://stock-news.laohu8.com/highlight/detail?id=1146912959","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146912959?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:14","pubTimestamp":1786526046,"startTime":"0","endTime":"0","summary":"RTW Investments, LP于2026年8月11日以每股均价26.05美元买入再鼎医药股份947.45万股，涉资约2.47亿美元。RTW Investments, LP此次增持前持有再鼎医药好仓6734.03万股，占比5.97%；增持后持股量为7681.48万股，好仓比例升至6.75%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658081928","title":"再鼎医药午前涨超5% 公司自主研发资产正逐步进入临床价值验证阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2658081928","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658081928?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:45","pubTimestamp":1786506300,"startTime":"0","endTime":"0","summary":"模拟交易客户端再鼎医药早盘一度涨超11%，绩后股价已累涨超三成。截至发稿，股价上涨5.13%，现报19.48港元，成交额3.59亿港元。再鼎医药今年二季度实现总收入为1.063亿美元，产品收入净额为1.058亿美元，环比增长11%，得益于则乐的稳定表现以及艾加莫德的销量持续增长。中信建投指出，公司自主研发资产正逐步进入临床价值验证阶段，核心自研管线有望于年内迎来密集数据读出及关键研发进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-12/doc-inimzqcr3698280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4526","LU2488822045.USD","BK4588","BK4531","ZLAB","BK1588","BK4585","BK4139","BK4548","09688","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658407879","title":"港股异动 | 再鼎医药(09688.HK)再涨超5% 核心管线迎来密集催化 创新将成下一阶段增长核心动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2658407879","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658407879?lang=zh_cn&edition=full","pubTime":"2026-08-12 10:53","pubTimestamp":1786503210,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09688","BK1588","BK1161","BK1574","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172809166","title":"异动解读｜再鼎医药盘中上涨8.04%，Q2业绩超预期及多管线催化持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1172809166","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172809166?lang=zh_cn&edition=full","pubTime":"2026-08-12 09:30","pubTimestamp":1786498253,"startTime":"0","endTime":"0","summary":"8月12日，再鼎医药盘中上涨8.04%，报20.04港元，成交额2728.71万港元。消息面上，公司于8月6日公布第二季度财务业绩，总收入1.063亿美元，产品收入净额1.058亿美元，环比增长11%，超出市场预期约250万美元，得益于则乐的稳定表现及艾加莫德销量持续增长。此外，宫颈癌新药缇乐获国家药监局批准上市，精神分裂创新药凯捷乐开出首张处方并放量，核心管线Zoci获欧洲药品管理局孤儿药资格认定，后续ESMO临床数据有望带来进一步催化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.3003},{"period":"3month","weight":0.4091},{"period":"6month","weight":0.3468},{"period":"1year","weight":-0.2345},{"period":"ytd","weight":0.5165}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0225},{"period":"3month","weight":0.0036},{"period":"6month","weight":-0.0271},{"period":"1year","weight":0.0212},{"period":"ytd","weight":0.0027}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.017355},{"month":2,"riseRate":0.666667,"avgChangeRate":0.068855},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.098942},{"month":4,"riseRate":0.666667,"avgChangeRate":0.061043},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.046017},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004904},{"month":7,"riseRate":0.666667,"avgChangeRate":0.052949},{"month":8,"riseRate":0.666667,"avgChangeRate":0.056494},{"month":9,"riseRate":0.4,"avgChangeRate":-0.054178},{"month":10,"riseRate":0.5,"avgChangeRate":-0.051338},{"month":11,"riseRate":0.5,"avgChangeRate":0.047251},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.024481}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}